Big pharma can ’t get enough of one class of cancer drugs
A world, dealmaking is in a rut. A combination of higher interest rates, geopolitical tensions and economic uncertainty has put a hold on joint ventures, mergers and acquisitions. One exception is targets with in their name. Another, less obvious one, involves a less catchy initialism: s. Makers…#seagen #nurixtherapeutics #amgen #astrazeneca #merck #daiichisankyo #bristolmyerssquibb #susangalbraith #trodelvy #gileadsciences (Source: Reuters: Health)
Source: Reuters: Health - December 18, 2023 Category: Consumer Health News Source Type: news
Lab Notes: AstraZeneca enters into $1.1B acquisition deal; Vittoria Biotherapeutics gets FDA clearance for lead therapy
This week's Lab Notes has items on a Big Pharma company's planned acquisition of a vaccine developer, a key FDA clearance for a Philadelphia early-stage cell therapy developer, a Penn Medicine milestone and more. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 15, 2023 Category: Pharmaceuticals Authors: John George Source Type: news
PET/CT shows impact of different COVID-19 vaccines
The type of COVID-19 vaccine and the time interval between vaccination and PET/CT scans are key factors in minimizing false interpretations in cancer patients, according to research published December 9 in Scientific Reports.
The study is the first to examine systemic response changes in patients in correlation to time after COVID-19 vaccination using three different vaccines, and may help minimize dilemmas for clinicians, wrote first author Tina Nazerani-Zemann, MD, of the Medical University of Graz in Austria, and colleagues.
“Different vaccines cause different system metabolic changes. The knowledge of vaccine type,...
Source: AuntMinnie.com Headlines - December 13, 2023 Category: Radiology Authors: Will Morton Source Type: news
AstraZeneca buys US vaccine company in $1.1bn deal
Britain ’s biggest drugmaker acquires Seattle-based firm Icosavax, expanding vaccine and immune therapy businessAstraZeneca is buying its first vaccine company in a $1.1bn deal that will expand the vaccine and immune therapy business it set up during the Covid-19 pandemic.Britain ’s biggest drugmaker has agreed to take over the Seattle-based company Icosavax, which is developing a potential vaccine for two common respiratory diseases.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - December 12, 2023 Category: Science Authors: Julia Kollewe Tags: AstraZeneca Pharmaceuticals industry Business Vaccines and immunisation Society Health Mergers and acquisitions Medical research Science Source Type: news
This Vaccine Stock Soars 47% After $1.1 Billion AstraZeneca Deal
Icosavax stock soared 47% in Tuesday premarket trading after the Seattle-based vaccine developer reached a deal to be acquired by pharmaceutical giant AstraZeneca.#seattle #astrazeneca (Source: Reuters: Health)
Source: Reuters: Health - December 12, 2023 Category: Consumer Health News Source Type: news
AstraZeneca Will Acquire RSV Vaccine Developer Icosavax For $1.1 Billion
The acquisition means AstraZeneca will gain access to Icosavax ’s experimental vaccine which targets both RSV and hMPV. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - December 12, 2023 Category: Pharmaceuticals Authors: Siladitya Ray, Forbes Staff Tags: Business /business Innovation /innovation Healthcare /healthcare Breaking breaking-news topline Source Type: news
AstraZeneca to acquire Icosavax
AstraZeneca has entered into a definitive agreement to acquire Icosavax, Inc. (NASDAQ: ICVX), a US-based clinical-stage biopharmaceutical company focused on developing differentiated, high-potential vaccines using an innovative, protein virus-like particle (VLP) platform.
The proposed acquisition will build on AstraZeneca's expertise in respiratory syncytial virus (RSV), strengthening AstraZeneca's Vaccines & Immune Therapies late-stage pipeline with Icosavax's lead investigational vaccine candidate, IVX-A12. IVX-A12 is a potential first-in- class, Phase III-ready, combination protein VLP vaccine which targets both RSV ...
Source: World Pharma News - December 12, 2023 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news
AstraZeneca strikes $1bn deal to acquire its first vaccine company
Anglo-Swedish pharma group agrees to buy Seattle-based biotech Icosavax (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - December 12, 2023 Category: Pharmaceuticals Source Type: news
National Resilience to create 440 new jobs at former AstraZeneca site in Greater Cincinnati
National Resilience is leveraging a massive Defense Department contract to create hundreds of new jobs at the former AstraZeneca site in West Chester. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 11, 2023 Category: Pharmaceuticals Authors: Brian Planalp Source Type: news
FACTBOX Novo, Lilly rivals explore booming weight-loss drug market entry
[1/2] An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. REUTERS/Mike Segar Acquire Licensing Rights Dec 8 (Reuters) - Novo Nordisk (NOVOb.CO) and Eli Lilly (LLY.N) have pulled ahead in the race for a slice of the…#anelilillyandcompany #imclonedrive #branchburg #newjersey #mikesegar #elilillyllyn #anglo #astrazeneca #novo #lilly (Source: Reuters: Health)
Source: Reuters: Health - December 9, 2023 Category: Consumer Health News Source Type: news
AstraZeneca, Absci sign $247M agreement to uncover AI-driven cancer drug candidates
The companies will leverage Absci ' s AI-enabled Integrated Drug Creation platform and the pharma giant ' s oncology research and development expertise. (Source: mobihealthnews)
Source: mobihealthnews - December 6, 2023 Category: Information Technology Source Type: news
Matan Companies Signs 198,000 SF Full-Building Lease with AstraZeneca at 700 Progress Way in Gaithersburg, MD
Part of a recently delivered 44-acre life science and industrial campus FREDERICK, Md., Dec. 6, 2023 /PRNewswire-PRWeb/ -- Matan Companies, a leading real estate development and investment firm, announced today the successful execution of a full-building lease agreement with AstraZeneca,... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 6, 2023 Category: Pharmaceuticals Tags: LIC Source Type: news
European Pharmas With New Drugs Hold Most Promise in 2024
European pharmaceutical and biotech companies with new drugs and higher growth prospects look the best investment bets in the sector in 2024, JPMorgan says. JPM is avoiding companies like Bayer and Roche, which might struggle to match 2024…#jpmorgan #jpm #bayer #roche #gsk #novonordisk #astrazeneca #merck #argenx #morphosys (Source: Reuters: Health)
Source: Reuters: Health - December 5, 2023 Category: Consumer Health News Source Type: news
The weight-loss drug gold rush is getting larger
More drug companies are racing to join what's been a two-horse race to make blockbuster obesity drugs, snapping up smaller biotechs and vying for a market that could be worth tens of billions in less than a decade. Why it matters: GLP-1 agonists like Novo Nordisk's Wegovy and Ozempic have soared…#glp1 #novonordisk #wegovyandozempic #medicare #zuercherkantonalbank #roche #carmottherapeutics #obese #carmot #astrazeneca (Source: Reuters: Health)
Source: Reuters: Health - December 5, 2023 Category: Consumer Health News Source Type: news
Absci announces another partnership with a major drugmaker
Absci's collaboration with AstraZeneca is intended to advance an AI-driven oncology candidate. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 4, 2023 Category: Pharmaceuticals Authors: Elizabeth Hayes Source Type: news
